Costs and Consequences of Using Interferon-γ Release Assays for the Diagnosis of Active Tuberculosis

Published Date:

04/28/2015

Source:

PubMed - NCBI

Authors:

Little KM, Pai M, Dowdy DW

External link

Original Article

There is growing concern that interferon-γ release assays (IGRAs) are being used off-label for the diagnosis of active tuberculosis (TB) disease in many high-burden settings, including India, where the background prevalence of latent TB infection is high. We analyzed the costs and consequences of using IGRAs for the diagnosis of active TB in India from the perspective of the Indian TB control sector.

Events

«

November 2017

»
S
M
T
W
T
F
S
·
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
·
·

Projects

Understanding the costs and...

We have conducted an empirical costing analysis of facility-based versus community-based treatment for TB in Bangladesh and are...

Read More

Statins as adjunctive host-directed therapy...

This study will investigate the role of statins in combination with the first-line regimen for TB in the mouse model. In...

Read More

Population-level impact of isoniazid...

We are collaborating with a team that conducted a randomized trial of IPT in Khayelitsha, South Africa, to extend their findings...

Read More

The role of cell wall lipids in pathogenesis...

This study will use a combination of transcriptional, lipidomic, genetic, and imaging techniques to investigate whether...

Read More

A randomized trial of preventive therapy for...

We are evaluating the efficacy and cost-effectiveness of levofloxacin preventive therapy for pediatric contacts of MDR TB...

Read More